Corcept Therapeutics | CORT - Cost Of Sales


Corcept Therapeutics reported $2.88M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Alaunos Therapeutics USD 0 18K Sep/2024
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Ardelyx USD 10.85M 6.87M Dec/2025
Assertio Holdings USD 8.89M 2.29M Jun/2024
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Canopy Growth CAD 53.08M 8.3M Dec/2025
Corcept Therapeutics USD 2.88M 338K Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
J&J USD 8.07B 103M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.46B 83M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 50.74M 3.89M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
TG Therapeutics USD 33.51M 4.63M Mar/2026